Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion
ObjectiveTo explore the oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion.MethodsThis study is a retrospective cohort study and retrospectively analyzed t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1322152/full |
| _version_ | 1827374983214530560 |
|---|---|
| author | Ju-Li Lin Ju-Li Lin Mi Lin Mi Lin Guang-Tan Lin Guang-Tan Lin Qing Zhong Qing Zhong Jun Lu Jun Lu Chao-Hui Zheng Chao-Hui Zheng Jian-Wei Xie Jian-Wei Xie Jia-bin Wang Jia-bin Wang Jia-bin Wang Chang-Ming Huang Chang-Ming Huang Chang-Ming Huang Ping Li Ping Li Ping Li |
| author_facet | Ju-Li Lin Ju-Li Lin Mi Lin Mi Lin Guang-Tan Lin Guang-Tan Lin Qing Zhong Qing Zhong Jun Lu Jun Lu Chao-Hui Zheng Chao-Hui Zheng Jian-Wei Xie Jian-Wei Xie Jia-bin Wang Jia-bin Wang Jia-bin Wang Chang-Ming Huang Chang-Ming Huang Chang-Ming Huang Ping Li Ping Li Ping Li |
| author_sort | Ju-Li Lin |
| collection | DOAJ |
| description | ObjectiveTo explore the oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion.MethodsThis study is a retrospective cohort study and retrospectively analyzed the clinicopathological data of 128 patients with serosal invasion gastric cancer (cT4NxM0) who received nab-paclitaxel + S-1(SAP) or camrelizumab + nab-paclitaxel + S-1 (C-SAP) regimen and underwent laparoscopy assisted gastrectomy in Fujian Union Hospital from March 2019 to December 2020. The patients were divided into SAP group and C-SAP group. The 2-years overall survival rate, 2-year recurrence free survival rate recurrence rate and initial recurrence time were compared between the two groups.ResultsA total of 128 patients were included, including 90 cases in SAP group and 38 cases in C-SAP group. There were no significant differences in age, gender, gastrectomy method, surgical approach, R0 resection, nerve invasion, vascular invasion, total number of harvested lymph nodes, number of positive lymph nodes and major pathologic response (MPR) rate between the two groups (P>0.05). However, the proportion of ypT0, ypN0 and pCR rate in C-SAP group were significantly higher than those in SAP group (P<0.05). The 2-year OS of C-SAP group (80.7%) was higher than that of SAP group (67.8%), and the difference was not statistically significant (P = 0.112); At 2 years after operation, the recurrence rate of C-SAP group (44.3%) was lower than that of SAP group (55.8%) (P = 0.097); Further analysis showed that the average time to recurrence in the C-SAP group was 18.9 months, which was longer than that in SAP group 13.1 months (P = 0.004); The 2-year recurrence free survival rate in C-SAP group was higher than that in SAP group (P=0.076); There was no significant difference in the overall survival time after recurrence between the two groups (P= 0.097).ConclusionCamrelizumab combined with neoadjuvant chemotherapy can improve the proportion of ypT0, ypN0 and pCR in patients, while prolonging the initial recurrence time of patients in the C-SAP group, but did not increase the immunotherapy/chemotherapy related side effects and postoperative complications. |
| first_indexed | 2024-03-08T11:43:12Z |
| format | Article |
| id | doaj.art-23a5720ab9f64f58a9a5e4f7f1399035 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T11:43:12Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-23a5720ab9f64f58a9a5e4f7f13990352024-01-25T04:17:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011510.3389/fimmu.2024.13221521322152Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasionJu-Li Lin0Ju-Li Lin1Mi Lin2Mi Lin3Guang-Tan Lin4Guang-Tan Lin5Qing Zhong6Qing Zhong7Jun Lu8Jun Lu9Chao-Hui Zheng10Chao-Hui Zheng11Jian-Wei Xie12Jian-Wei Xie13Jia-bin Wang14Jia-bin Wang15Jia-bin Wang16Chang-Ming Huang17Chang-Ming Huang18Chang-Ming Huang19Ping Li20Ping Li21Ping Li22Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaKey Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaKey Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, ChinaDepartment of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaDepartment of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, ChinaKey Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, ChinaObjectiveTo explore the oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion.MethodsThis study is a retrospective cohort study and retrospectively analyzed the clinicopathological data of 128 patients with serosal invasion gastric cancer (cT4NxM0) who received nab-paclitaxel + S-1(SAP) or camrelizumab + nab-paclitaxel + S-1 (C-SAP) regimen and underwent laparoscopy assisted gastrectomy in Fujian Union Hospital from March 2019 to December 2020. The patients were divided into SAP group and C-SAP group. The 2-years overall survival rate, 2-year recurrence free survival rate recurrence rate and initial recurrence time were compared between the two groups.ResultsA total of 128 patients were included, including 90 cases in SAP group and 38 cases in C-SAP group. There were no significant differences in age, gender, gastrectomy method, surgical approach, R0 resection, nerve invasion, vascular invasion, total number of harvested lymph nodes, number of positive lymph nodes and major pathologic response (MPR) rate between the two groups (P>0.05). However, the proportion of ypT0, ypN0 and pCR rate in C-SAP group were significantly higher than those in SAP group (P<0.05). The 2-year OS of C-SAP group (80.7%) was higher than that of SAP group (67.8%), and the difference was not statistically significant (P = 0.112); At 2 years after operation, the recurrence rate of C-SAP group (44.3%) was lower than that of SAP group (55.8%) (P = 0.097); Further analysis showed that the average time to recurrence in the C-SAP group was 18.9 months, which was longer than that in SAP group 13.1 months (P = 0.004); The 2-year recurrence free survival rate in C-SAP group was higher than that in SAP group (P=0.076); There was no significant difference in the overall survival time after recurrence between the two groups (P= 0.097).ConclusionCamrelizumab combined with neoadjuvant chemotherapy can improve the proportion of ypT0, ypN0 and pCR in patients, while prolonging the initial recurrence time of patients in the C-SAP group, but did not increase the immunotherapy/chemotherapy related side effects and postoperative complications.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1322152/fullGastric cancer with serous invasionCamrelizumabNeoadjuvant chemotherapy2-years overall survival rate2-year recurrence free survival rate |
| spellingShingle | Ju-Li Lin Ju-Li Lin Mi Lin Mi Lin Guang-Tan Lin Guang-Tan Lin Qing Zhong Qing Zhong Jun Lu Jun Lu Chao-Hui Zheng Chao-Hui Zheng Jian-Wei Xie Jian-Wei Xie Jia-bin Wang Jia-bin Wang Jia-bin Wang Chang-Ming Huang Chang-Ming Huang Chang-Ming Huang Ping Li Ping Li Ping Li Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion Frontiers in Immunology Gastric cancer with serous invasion Camrelizumab Neoadjuvant chemotherapy 2-years overall survival rate 2-year recurrence free survival rate |
| title | Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion |
| title_full | Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion |
| title_fullStr | Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion |
| title_full_unstemmed | Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion |
| title_short | Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion |
| title_sort | oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab paclitaxel plus s 1 for gastric cancer with serosal invasion |
| topic | Gastric cancer with serous invasion Camrelizumab Neoadjuvant chemotherapy 2-years overall survival rate 2-year recurrence free survival rate |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1322152/full |
| work_keys_str_mv | AT julilin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT julilin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT milin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT milin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT guangtanlin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT guangtanlin oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT qingzhong oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT qingzhong oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT junlu oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT junlu oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT chaohuizheng oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT chaohuizheng oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT jianweixie oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT jianweixie oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT jiabinwang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT jiabinwang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT jiabinwang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT changminghuang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT changminghuang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT changminghuang oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT pingli oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT pingli oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion AT pingli oncologicaloutcomesofsequentiallaparoscopicgastrectomyaftertreatmentwithcamrelizumabcombinedwithnabpaclitaxelpluss1forgastriccancerwithserosalinvasion |